Injection Therapy for Neuropathic Pain
- Conditions
- Neuropathic Pain
- Interventions
- Drug: Freshly manufactured 35 kDa hyaluronan fragment
- Registration Number
- NCT05809700
- Lead Sponsor
- Dove Medical Press Ltd
- Brief Summary
Shoulder, neck, back and temporal pain and herpes zoster pain are neuropathic pain. Preliminary clinical studies have confirmed that injection of freshly prepared HA35 can relieve neuropathic pain. This clinical study is a prospective repeated experiments. The purpose of this study was to verify the effectiveness of HA35 injection therapy.
- Detailed Description
In this study, the recombinant human hyaluronidase PH20 and neutral hyaluronidase (PH20) of bovine testicular sperm acrosomes were used to cleave macromolecular HA. Regardless of the cutting time, the HA fragment HA35, with an average molecular weight of 35 kDa, was produced (Registration number L20200708MP07707, Ministry of Health, Mongolia). Hyaluronidase is often used to improve the penetration and absorption of other injectable drugs. Hyaluronidase injection is also used off label to degrade excessive components used in cosmetic injections, such as cross-linked macromolecular HA fillers (https://www.realself.com/news/hyaluronidase-dissolve-fillers). In this study, HA35 was prepared by mixing hyaluronidase extracted from bovine testis (hyaluronidase for injection, H31022111) and HA (sodium hyaluronate for injection, H20174089) at room temperature for 20 minutes. The analgesic effect of HA35 on herpes zoster and shoulder, neck, back, and temporal pain was studied. This was a single-arm, open-label prospective clinical study in which patients were evaluated before and after treatment.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 36
- The course of neck, back and temporal pain ranged from 0 to 8 months.
- The course of herpes zoster of 0-2 months.
- Adults aged 18-60 years.
- Be willing and capable of giving informed consent.
- Have a clinical diagnosis of neuropathic pain as determined by a multidisciplinary study team.
- Subject must sign the informed consent in person prior to beginning any screening procedure.
- Have a persistent pain resulted from other medical conditions or unknown causes.
- Pregnant females.
- Be concomitantly participating in another clinical study.
- Have been immunocompromised.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description HA35 local injection of pain location Group Freshly manufactured 35 kDa hyaluronan fragment According to the ratio of 100 mg high molecular weight HA (sodium hyaluronate for injection, H20174089)/2000 units of hyaluronidase extracted from bovine testis (hyaluronidase for injection H31022111), high molecular weight HA injection and hyaluronidase injection were mixed at room temperature for 20 minutes.
- Primary Outcome Measures
Name Time Method the Numerical Pain Rating Scale (NPRS) scores 30 min to 3 hours The pain scale used is a tool that doctors use to help assess patients' pain. Each patient rated their pain on a scale of 0 to 10. A score of 0 means "no pain" and 10 means "the most painful". Statistical t-tests were used to calculate and evaluate the pain intensity, which were expressed as the mean ± standard deviation.
the General Comfort Questionnaire (GCQ) scores 24 hours Using 1-4 grade scoring method, that is, 1 means ' very disagree ', 2 means ' disagree ', 3 means ' agree ', 4 means ' very agree'. The total score is less than 60 points for low comfort, 60-90 points for moderate comfort, and more than 90 points for high comfort.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Huinuode Biotechnology Co., Ltd.
🇨🇳Qingdao, Shandong, China